Semaglutide 2.4 mg Subcutaneous for Weight Loss: 68-Week Trial Outcomes
In the 68-week STEP trials, subcutaneous semaglutide 2.4 mg once weekly achieved mean weight loss of 14.9-16.0% compared to 2.4-5.7% with placebo, with dosing escalated from 0.25 mg over 16 weeks to the maintenance dose of 2.4 mg 1.
Dosing Protocol
The medication follows a structured 16-week dose escalation schedule 2:
- Week 1-4: 0.25 mg once weekly
- Week 5-8: 0.5 mg once weekly
- Week 9-12: 1.0 mg once weekly
- Week 13-16: 1.7 mg once weekly
- Week 17-68: 2.4 mg once weekly (maintenance dose)
This gradual titration minimizes gastrointestinal adverse events, which are the most common side effects 2.
Efficacy Outcomes at 68 Weeks
Weight Loss Results
The STEP 1 and STEP 3 trials demonstrated robust efficacy in adults with obesity (mean BMI 38) without diabetes 1:
- STEP 1: Mean weight loss of 14.9% (placebo: 2.4%; difference: 12.4 percentage points; 95% CI, 11.5-13.4%) 1, 3
- STEP 3: Mean weight loss of 16.0% (placebo: 5.7%; difference: 10.3 percentage points; 95% CI, 8.6-12.0%) 1, 4
In absolute terms, STEP 1 participants lost a mean of 15.3 kg versus 2.6 kg with placebo (difference: 12.7 kg) 3.
Categorical Weight Loss Achievement
The proportion of participants achieving clinically meaningful weight loss thresholds was substantially higher with semaglutide 3:
- ≥5% weight loss: 86.4% vs 31.5% placebo (p<0.001)
- ≥10% weight loss: 69.1% vs 12.0% placebo (p<0.001)
- ≥15% weight loss: 50.5% vs 4.9% placebo (p<0.001)
Cardiometabolic Benefits
Beyond weight loss, semaglutide improved cardiovascular risk factors and quality of life 1:
- Reduced cardiovascular events in the SELECT study (HR 0.80; 95% CI, 0.72-0.90) in patients with established CVD 1
- Improved physical functioning scores on SF-36 questionnaires 3
- Enhanced glycemic control and lipid profiles 1
Lifestyle Intervention Components
STEP 1 combined semaglutide with 1, 3:
- Reduced-calorie diet
- 150 minutes/week of physical activity
STEP 3 used more intensive behavioral therapy 1, 4:
- 8-week low-calorie meal replacement phase
- Reduced-calorie diet thereafter
- 200 minutes/week of physical activity goal
- 30 individual dietitian visits over 68 weeks
Despite more intensive lifestyle intervention in STEP 3, weight loss was only marginally greater (16.0% vs 14.9%), suggesting the medication effect predominates 1.
Critical Caveat: Lifelong Treatment Necessity
Weight regain after discontinuation is substantial and rapid, making long-term continuous use essential 1, 5:
- After completing 68 weeks of treatment, participants who stopped semaglutide regained 11.6% of lost weight over the subsequent 52 weeks 1
- In STEP 4, switching from semaglutide to placebo after 20 weeks resulted in 6.9% weight regain over 48 weeks, while those continuing semaglutide lost an additional 7.9% 5
This underscores that semaglutide must be used lifelong for sustained weight management—it is not a time-limited intervention 1.
Safety Profile
Gastrointestinal adverse events were the most common, typically mild-to-moderate and transient 1, 3, 4:
- Nausea: ~40% (vs 14.8% placebo)
- Diarrhea: Common but usually self-limited
- Treatment discontinuation due to GI events: 4.5% vs 0.8% placebo 3
The gradual dose escalation protocol is specifically designed to mitigate these effects 2.
Comparison to Other Formulations
Oral semaglutide 50 mg daily achieved similar weight loss (15.1% at 68 weeks) but is not yet FDA-approved for obesity alone 1. Subcutaneous semaglutide 2.4 mg weekly demonstrated superior weight loss compared to liraglutide 3.0 mg daily (15.8% vs 6.4% at 68 weeks) with lower gastrointestinal adverse event rates 1, 6.
Patient Selection
Semaglutide 2.4 mg is indicated for adults with 1:
- BMI ≥30 kg/m² (obesity), OR
- BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease)
The medication should be combined with lifestyle modifications and patients must be counseled about the need for lifelong use to maintain weight loss 1.